SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo-Reference-Cited by-同舟云学术

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Published:2018-05-28 Issue:7 Volume:24 Page:961-967
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Mainardi Sara,Mulero-Sánchez Antonio,Prahallad Anirudh,Germano Giovanni,Bosma Astrid,Krimpenfort Paul,Lieftink Cor,Steinberg Jeffrey D.,de Wit Niels^ORCID,Gonçalves-Ribeiro Samuel,Nadal Ernest,Bardelli Alberto,Villanueva Alberto,Bernards Rene^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0023-9.pdf

Reference37 articles.

1. Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).

2. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584–594 (2008).

3. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011).

4. Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging Ras back in the ring. Cancer Cell 25, 272–281 (2014).

5. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012).

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-05

2. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09

3. Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors;European Journal of Medicinal Chemistry;2024-09

4. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer;Signal Transduction and Targeted Therapy;2024-08-21

5. SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling;Nature Communications;2024-08-13